Persons living with human immunodeficiency virus (HIV) (PLWH) infection have an increased cancer risk due to HIVinduced immunosuppression, coinfections with oncogenic viruses, and high prevalence of behavioral risk factors for cancer such as smoking [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Besides the AIDS-defining cancers (ADCs)-that is, Kaposi sarcoma (KS), certain non-Hodgkin lymphomas (NHLs), and cervical cancer-the risks of some non-AIDS-defining cancers (NADCs), including lung, liver, anal, and oral cavity/pharyngeal cancers, and Hodgkin lymphoma are also increased [2, [5] [6] [7] [8] [9] [10] .
The introduction of highly active antiretroviral therapy (HAART) has led to a steady increase in the life expectancy of PLWH [11] . Consequently, the number of older PLWH in the United States has also increased. In 2014, approximately 44% of PLWH in the United States were aged ≥50 years, and 17% of new HIV diagnoses were made in this age group [12, 13] . Because of improved immunity due to HAART, rates of ADCs have declined over the past 2 decades [7, 14, 15] . However, rates of many NADCs increase with age. It is unclear whether age-related immune senescence in the setting of HIV-related immunosuppression will result in particularly elevated cancer rates among older PLWH.
PLWH aged ≥50 years are a heterogeneous group including long-term survivors who have lived with HIV infection for many years and individuals with newly diagnosed infection; whether cancer risk varies based on the duration of HIV infection is uncertain. Prolonged immunosuppression in those with long-term HIV infection may increase cancer risk. Alternatively, persons with HIV infection newly diagnosed at an older age may have more severe immunosuppression and a consequent high risk for cancer. Such persons may present late with a lower CD4 + T-cell count, later HAART initiation, and more rapid progression to AIDS than young PLWH [16] [17] [18] [19] .
As the proportion of older PLWH continues to grow, a comprehensive evaluation of cancer risk in this population is needed. We therefore examined cancer risk in older PLWH compared with the general population, and we evaluated the effects on cancer risk of age and time since HIV diagnosis.
SUBJECTS AND METHODS

Study Population and Outcomes
The US HIV/AIDS Cancer Match study links data from population-based HIV and cancer registries using a probabilistic algorithm (https://hivmatch.cancer.gov) [14] . This analysis included data from 9 US states/territories (see footnote to Table 1 ). This study was approved by the institutional review boards at the National Cancer Institute and, as required, by participating cancer and HIV registries.
The HIV diagnosis date was identified from HIV registries as the date of the first available positive serological test for HIV infection. The follow-up for each person started at the later of the start of cancer registry coverage, 4 months after the HIV report date (or AIDS diagnosis date if earlier), or at age 50 years, and it ended at death or the end of cancer registry coverage, whichever came first.
We evaluated the risks of ADCs-KS, cervical cancer, and NHL (overall and by subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, primary central nervous system [CNS] lymphoma, and other/unspecified NHLs)-and certain NADCs with increased incidence among PLWH: cancers of the anus, lung, liver, and oral cavity/pharynx and Hodgkin lymphoma [5] . Female breast, colon, and prostate cancers were also included; although their rates increase with age, they are not elevated among PLWH [5] . The remaining cancers were grouped together in a separate category. Cancers were classified using the International Classification of Diseases for Oncology (third edition) topography and morphology codes for invasive cancers (Supplementary Table S1 ) [20] .
Statistical Analyses
We compared cancer incidence rates between PLWH and the general population by calculating standardized incidence ratios (SIRs), which measure relative risk, and excess absolute risks (EARs), which measure absolute risk. SIRs were calculated as the observed divided by the expected number of cases; expected cases were estimated by applying general population cancer incidence rates to the HIV population by age, sex, race/ethnicity, calendar year, and cancer registry. Because the AIDS epidemic affected the contemporaneous rates of KS and primary CNS lymphoma in the general population, we calculated the expected number of cases for these cancers with pre-AIDS epidemic (1973) (1974) (1975) (1976) (1977) (1978) (1979) incidence rate ratios (aIRRs) were adjusted for race/ethnicity, sex/risk group, calendar year, region, prior AIDS diagnosis, and time since HIV diagnosis (in models for age) or age (in models for time since HIV diagnosis). Age, calendar year, prior AIDS diagnosis, and time since HIV diagnosis variables were updated over time. We conducted some sensitivity analyses. Because outmigration of persons from registry areas may result in overestimating the person-time at risk, we decreased the person-time by 10% for PLWH after 10 years of follow-up and recalculated the SIRs [22] . It is possible that more cancer cases may be diagnosed shortly after HIV infection because there may be a period of increased medical care around that time. Hence, we excluded the first year after HIV diagnosis date and reestimated cancer risk according to time since HIV diagnosis. Because the risk of ADCs and NADCs have changed since the introduction of HAART, we restricted the follow-up time to calendar years 2001-2012 and recalculated the SIRs and aIRRs. Finally, we evaluated whether associations between age and cancer risk differed by time since HIV diagnosis, and whether associations between time since HIV diagnosis and cancer risk differed by age.
RESULTS
We studied 183 542 PLWH aged ≥50 years old who contributed 928 194 person-years of follow-up ( Table 1 ). The person-time distribution was 75.1% in 50-59-year-olds, 20.4% in 60-69-year-olds, and 4.5% in those aged ≥70 years. A large fraction of person-time was contributed by non-Hispanic blacks (47.6%), men (74.3%), and those with a prior AIDS diagnosis (71.9%). A large proportion of person-time for the time since HIV diagnosis was unknown (22.2%). Among PLWH with a known date of HIV diagnosis, >60% were infected with HIV for ≥5 years, and approximately 20% had been living with HIV infection for >15 years.
During the follow-up, 10 371 cancers were diagnosed, of which 1647 (15.9%) were ADCs and 8724 (84.1%) were NADCs ( Table 2) . As expected, rates were increased in older PLWH compared with the general population for KS (SIR, 103.34), total NHL (3.05), and cervical cancer (2.02). Among NHLs, rates were strongly elevated for CNS lymphoma (SIR, 47.39) and Burkitt lymphoma (13.75). Among the NADCs, a very high risk of anal cancer (SIR, 14.00) was observed, followed by Hodgkin lymphoma (7.61). Rates were moderately increased for liver (SIR, 2.91), lung (1.71), and oral cavity/pharyngeal cancers (1.66). Furthermore, rates of breast (SIR, 0.61), prostate (0.47), and colon cancer (0.63) were significantly lower among PLWH than in the general population. The SIRs did not differ appreciably after the person-time was adjusted for late follow-up, or when analyses were restricted to calendar years 2001-2012 (Supplementary Tables S2 and S4) .
A comparison of SIRs and EARs by age for evaluated cancers is depicted in Figure 1 . The SIRs were the highest for the youngest age group (<50 years) for all cancers and decreased with age, except for Hodgkin lymphoma, for which the SIRs were largely constant. The EARs also decreased with age for KS, NHL, cervical cancer, and Hodgkin lymphoma. In contrast, the EARs increased with age for cancers of the anus, lung, liver, and oral cavity/pharynx.
Examining cancer incidence rates among PLWH by age group (Table 3) , we observed a significant decrease in KS risk with increasing age. Compared with 50-59-year-olds, PLWH aged 60-69 (aIRR, 0.68) or ≥70 ( 0.43) years had lower KS rates (P trend = .001). In contrast, rates for lung, prostate, and colon cancers increased with age (P trend < .001) while the increasing trend for breast cancer was borderline significant (P trend = .058). Liver and oral cavity/pharyngeal cancer rates were higher among 60-69-year-olds than in the 50-59-year age group (P trend < .05).
No association between age and cancer risk was observed for NHL (total or subtypes), cervical cancer, anal cancer, or Hodgkin lymphoma (P trend > .05). PLWH with a prior AIDS diagnosis had increased rates of KS, NHL (particularly diffuse large B-cell lymphoma [aIRR, 1.97] and CNS lymphomas [5.17] ), anal, lung, and oral cavity/pharyngeal cancer, and Hodgkin lymphoma than those without a previous AIDS diagnosis (aIRRs range, 1.37-2.66; Table 3 ). Prostate cancer rates were lower among those with a prior AIDS diagnosis (aIRR, 0.84), but rates of cervical, liver, breast, and colon cancer did not differ significantly .
The risk of most cancers was highest within the first 5 years after HIV diagnosis, gradually decreasing over time (Table 4 ). Significant decreasing trends were observed for KS (P trend < .001), total NHL (P trend < .001), lung cancer (P trend < .001), breast cancer (P trend = .02), and Hodgkin lymphoma (P trend = .04), with a marginally significant trend for prostate cancer (P trend = .07). In contrast, there was an indication that risk increased with increasing time since HIV diagnosis for anal (P trend = .07) and liver (P trend = .08) cancers. Excluding the first year after HIV diagnosis did not affect our results (Supplementary Table S3 ). Restricting the analyses to calendar years 2001-2012 did not affect the associations between age or time since HIV diagnosis and cancer risk (Supplementary Tables S5 and S6 ).
The associations between age and cancer risk did not differ by time since HIV diagnosis for all cancers (all P interaction > .05). However, there was significant heterogeneity in the association between time since HIV diagnosis and cancer risk by age for NHL (P interaction = .003) and Hodgkin lymphoma (P interaction = .02).
The aIRRs for NHL decreased with time since HIV diagnosis for both age categories (P trend < .001 for ages 50-59 and ≥60 years). For Hodgkin lymphoma, the trend for decreasing rates with time since HIV diagnosis was observed only for ≥60-year-olds (P trend = .006) and not among those aged 50-59 years (P trend = .41).
DISCUSSION
With the success of HAART, HIV infection has been transformed from a terminal illness to a more manageable chronic disease. Consequently, more PLWH are reaching older ages. In our analyses that included >180 000 older PLWH, we observed that cancer risk was elevated in older PLWH compared with the general population, although the relative risk for most cancers declined with age. However, EARs, which measure absolute risk and thus reflect the number of excess cancers occurring among PLWH, increased with age for some NADCs. We also observed that for many cancers, cancer risk was highest within the first 5 years after HIV diagnosis.
In the past 20 years, there has been a steady shift in the demographic profile of the HIV/AIDS epidemic in the United States toward older age groups. In 2002, the Centers for Disease Control and Prevention estimated that approximately 8.5% of PLWH were >50 years of age, and that proportion had increased to 44% in 2014 [12] . With aging, there is a complex interaction between various biological processes which may modulate cancer risk among PLWH: (1) factors related to aging, including [23] . HAART alters the natural history of HIV infection with gradual improvement of immunosuppressive state and restoration of CD4 + T-cell count over time. In addition, the duration of immunosuppression in a person infected with HIV also increases with time. Few previous studies have been able to evaluate cancer risk in older PLWH because this population has historically been too small to target [24, 25] . In our study, we observed that the risk of ADCs and certain NADCs were elevated in older PLWH compared with the general population, as has been previously reported in mostly young PLWH [3, 7, 26] . Because cancer risk increases with age, and PLWH are at a high risk for cancer, the aging of PLWH raises the question of whether the combined effect of age and HIV infection will further increase cancer risk in PLWH. As captured by SIRs, we did not observe an amplified cancer risk associated with aging among PLWH. In fact, the SIRs were highest for the young PLWH and declined with age, except for Hodgkin lymphoma, suggesting that HIV-related immunosuppression may play a larger role in cancer development in younger groups.
Although the risk of anal, lung, liver, and oral cavity/pharyngeal cancers in PLWH relative to the general population decreased with age, the excess cancer rates increased in absolute terms, as reflected in the EARs. Owing to increasing cancer incidence in the general population with age, even a modest decrease in SIRs with advancing age could lead to an increase in EARs and thus number of cancer cases. Thus, as PLWH continue to age, we may continue to observe an increase in the absolute number of these NADCs.
Risks for KS, NHLs, Hodgkin lymphoma, and lung and breast cancer were highest within the first 5 years after HIV diagnosis. The intensity of immunosuppression may be highest in the initial period, when PLWH with newly diagnosed infection are untreated and may be especially immunosuppressed [27, 28] . Alternatively, it is possible that persons who survived for several years with HIV infection may represent a healthy subset of PLWH, whereas those with newly acquired and diagnosed HIV infection may have a higher prevalence of cancer risk factors. For example, a diagnosis of HIV infection may lead to changes in lifestyle habits, such as reducing cigarette smoking [29] . Increased medical surveillance shortly after HIV diagnosis may also increase the possibility of detecting cancers, but excluding the first year of follow-up after HIV diagnosis did not eliminate the trend that we observed. In contrast, anal and liver cancer rates marginally increased with time since HIV diagnosis, which may represent the role of prolonged immunosuppression in increasing cancer rates due to human papillomavirus or hepatitis virus coinfections. We observed lower risk of breast, prostate, and colon cancer rates in older PLWH compared with the general population, as reported elsewhere [26, [30] [31] [32] [33] . As in the general population, prostate and colon cancer rates increased with age, and the trend for breast cancer was borderline significant. Because these are common screen-detectable cancers, it has been speculated that their reduced rates may reflect lower rates of cancer screening among PLWH compared with the general population. However, recent studies suggest that the deficit of breast, colon, and prostate cancers among PLWH cannot be completely explained by lower rates of cancer screening [34, 35] . Biological explanations for these deficits need to be explored further.
Given the aging of PLWH and the increase in the burden of NADCs, it is essential to target available cancer prevention and screening strategies toward this population. Cancer prevention among PLWH is largely based on restoring immunity with HAART and reducing established cancer risk factors [36] . Timely linkage of care with HAART initiation and uninterrupted treatment for persons in whom HIV infection has been newly diagnosed is essential to restore immunity. This also gives an opportunity for healthcare providers to diagnose and treat coinfections and to initiate counseling on modification of lifestyle behaviors, such as smoking. General population screening guidelines for breast, prostate, and colon cancers should be followed. Cervical cancer screening is recommended at more frequent intervals than for HIV-uninfected women [37, 38] , and the benefits of anal cancer screening are still being evaluated [37, 38] . Finally, screening for lung cancers with low-dose computed tomography may be beneficial, but more data are needed among PLWH [37, 38] .
Strength of our study included the use of a large population-based cohort of >180 000 PLWH aged ≥50 years with systematic cancer ascertainment and the evaluation of cancer risk by time since HIV diagnosis. However, we were unable to include information on HAART use, CD4 + T-cell count, or HIV viral load in our analyses. Therefore, we cannot definitively interpret trends with respect to time since HIV diagnosis. In addition, our data do not include information about cancer risk factors, such as cigarette smoking and viral coinfection. Because the timing of HIV acquisition was not known, the duration of HIV infection could be calculated only from the first available positive serological test date, and we were missing this information for 22.2% of person-time contributed by PLWH in our study. We were unable to adjust for competing risks due to coexisting comorbid conditions in our analyses. We used the general population as our control group because we did not have access to an ideal HIV-uninfected population that may have similar characteristics to PLWH [39] . Finally, our analysis includes only PLWH in whom HIV infection has been diagnosed, and an estimated 13% of PLWH are unaware that they are infected, >7% of whom may be >50 years of age [40] .
In conclusion, rates of several cancer types are elevated in older PLWH compared with the general population, albeit in the absence of information on important cancer risk factors. However, the relative risk of cancers is lower than for younger PLWH, suggesting that the combined effect of aging and HIV does not further amplify the relative risk of cancers. Despite lower relative risks, the absolute risk difference is higher for some NADCs among older PLWH, leading to a greater incidence of excess cancers in this group. Thus, there is a continued need for cancer prevention and early detection among older PLWH. Cancer risk was also highest within the first 5 years after HIV diagnosis for most cancers, underscoring the importance of early HIV diagnosis, rapid initiation of HAART after HIV diagnosis, and interventions to reduce known risk factors in older PLWH.
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